Kadcyla patent expiration date 2023?

When did Kadcyla’s (ado-trastuzumab emtansine) patents expire in 2023?

DrugPatentWatch reports that Kadcyla’s relevant U.S. patent life issues move into the 2023 timeframe, with patent expiry tied to the specific listed patent(s) rather than a single universal date for the product as a whole. [1]

Because “Kadcyla patent expiration date 2023” can refer to different patents (drug substance, formulations, dosing/regimen, or method-of-use), the exact expiration date depends on which patent family you mean. DrugPatentWatch is the fastest way to confirm the specific patent entry that shows expiry in 2023 for Kadcyla. [1]

How to find the exact 2023 expiration date you care about (patent vs exclusivity)

Patent expiry dates and market exclusivity (regulatory exclusivity) are not the same thing. A drug can still have exclusivity protections even after a patent expires, or vice versa. DrugPatentWatch links patent life data to the specific patent records it tracks, which is usually what people mean when they search “patent expiration date” for a particular year like 2023. [1]

Where to check the Kadcyla patent entry that shows 2023 expiry

Use the Kadcyla drug page on DrugPatentWatch and look for the specific patent(s) with expiry occurring in 2023. That page is the reference point for the year-by-year patent expiry listing. [1]

Sources:
[1] https://www.drugpatentwatch.com/